Lenalidomid Sandoz

Lenalidomide, the active ingredient in Lenalidomid Sandoz, is an immunomodulatory agent presented as an oral formulation for systemic use. It is indicated for the treatment of multiple myeloma and certain myelodysplastic syndromes in adult patients.

GNH USA supplies Lenalidomid Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring consistent quality, regulatory conformity and reliable delivery across global markets.

Lenalidomid Sandoz, an immunomodulatory agent, is used in hematologic malignancies and related disorders.

- Multiple myeloma: improves response rates and delays disease progression. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and cytopenias. - Relapsed or refractory mantle cell lymphoma (in combination therapy): contributes to tumor control.

Lenalidomid Sandoz may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: low platelet levels that may cause bleeding. - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that can lead to dehydration.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe cutaneous reactions: such as Stevens‑Johnson syndrome. - Secondary primary malignancies: emergence of new cancers during therapy.

When prescribing Lenalidomid Sandoz, clinicians should observe several safety measures.

- Monitor blood counts: perform regular CBC to detect cytopenias. - Assess thrombotic risk: consider prophylactic anticoagulation in high‑risk patients. - Avoid pregnancy: use effective contraception during treatment and for at least four weeks after discontinuation. - Renal impairment: adjust dose or monitor closely in patients with reduced clearance. - Drug interactions: review concomitant medications for CYP or immunosuppressive agents. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original container.

Lenalidomid Sandoz can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce lenalidomide exposure. - Anticoagulants (warfarin): increased risk of bleeding. - Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Antiplatelet agents (aspirin): additive myelosuppression. - Immunosuppressants (cyclosporine): may increase toxicity. - Hormonal contraceptives: reduced efficacy, consider alternative contraception.